Completed Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons NCT05683834 Conditions DNA Virus Infections, Epstein-Barr Virus Infection, Epstein-Barr Virus Infections, +18 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States University of Minnesota — Minneapolis, Minnesota, United States View Trial Details
